The World Health Organization says a trial Ebola Fever Immunogen has been observed to be amazingly defensive against the ferocious infection in a major trial in Guinea
"The immunization is the first to keep contamination from a standout amongst the most deadly known pathogens, and the discoveries add weight to early trial comes about distributed a year ago," WHO said in a public statement.
The UN health agency noticed the aftereffects of the most recent trial distributed on Friday in the restorative diary The Lancet.
As indicated by WHO, the vaccine, 'rVSV-ZEBOV', was considered in a trial involving 11,841 individuals in Guinea during 2015.
It said among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination.
In comparison, there were 23 cases in 10 days or more after vaccination among those who did not receive the vaccine, the global health organisation said.
The report quoted Dr. Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation, and the study’s lead author, as saying the result was “defensive” against future Ebola outbreaks.
"While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," Kieny said.
The Ebola infection was initially recognized in 1976 and brought on sporadic outbreaks in Africa.
However, the 2013-2016 outbreaks in West Africa that killed more than 11,300 people underlined the urgent need of a vaccine.
Guinea, along with Liberia and Sierra Leone, was one of the worst affected countries.
Dr KeÏta Sakoba, the Coordinator of the Ebola Response and Director of Guinea’s National Agency for Health Security, noted the significance of the latest results.
“We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured,” Sakoba said.
The reports said the trial took place in the coastal region of Basse-Guinée, the area of Guinea still experiencing new Ebola cases when the trial started in 2015.
"It employed an innovative design, a so-called `ring vaccination' approach – the same method used to eradicate small pox.
"This involved tracing all people who may have been in contact with a new Ebola case within the previous three weeks as well as certain contacts of contacts."
In addition to showing high efficacy among those vaccinated, it said the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach.
However, the authors noted that the trial was not designed to measure this effect, so more research will be needed.
 |
| Ebola |
The UN health agency noticed the aftereffects of the most recent trial distributed on Friday in the restorative diary The Lancet.
As indicated by WHO, the vaccine, 'rVSV-ZEBOV', was considered in a trial involving 11,841 individuals in Guinea during 2015.
It said among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination.
In comparison, there were 23 cases in 10 days or more after vaccination among those who did not receive the vaccine, the global health organisation said.
The report quoted Dr. Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation, and the study’s lead author, as saying the result was “defensive” against future Ebola outbreaks.
"While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," Kieny said.
The Ebola infection was initially recognized in 1976 and brought on sporadic outbreaks in Africa.
However, the 2013-2016 outbreaks in West Africa that killed more than 11,300 people underlined the urgent need of a vaccine.
Guinea, along with Liberia and Sierra Leone, was one of the worst affected countries.
Dr KeÏta Sakoba, the Coordinator of the Ebola Response and Director of Guinea’s National Agency for Health Security, noted the significance of the latest results.
“We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured,” Sakoba said.
The reports said the trial took place in the coastal region of Basse-Guinée, the area of Guinea still experiencing new Ebola cases when the trial started in 2015.
"It employed an innovative design, a so-called `ring vaccination' approach – the same method used to eradicate small pox.
"This involved tracing all people who may have been in contact with a new Ebola case within the previous three weeks as well as certain contacts of contacts."
In addition to showing high efficacy among those vaccinated, it said the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach.
However, the authors noted that the trial was not designed to measure this effect, so more research will be needed.
Thank God ooo
ReplyDelete